ArticlePloS one2025
Uncovering biomarkers and molecular pathways linking NAFLD and AIS: Insights from bioinformatic analysis and experiment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) and acute ischemic stroke (AIS) are both closely related to chronic inflammation and metabolic disorders, but the molecular mechanisms between them are not yet clear. This study aims to explore the common molecular characteristics between NAFLD and AIS using bioinformatics methods.
methodsWe integrated transcriptomic data from GEO (GSE89632 for NAFLD and GSE16561 for AIS) to identify shared molecular signatures. Differentially expressed genes (DEGs) were screened using the limma package, and co-expression modules were identified via WGCNA. Functional enrichment and immune infiltration analyses were conducted using standard bioinformatics tools. Key genes were selected through LASSO and random forest algorithms, and candidate drugs were predicted using the CMap database. Experimental validation included qPCR, immunohistochemistry, and drug intervention in HepG2 and HMC3 cell models, as well as a high-fat diet-induced NAFLD mouse model.
resultsThrough differential expression analysis, 65 common DEGs were identified in both NAFLD and AIS. Functional enrichment analysis showed that these genes mainly involve signal pathways related to immune regulation and inflammatory responses. Immune infiltration analysis showed a significant increase in monocytes, B cells, and plasma cells in NAFLD patients. Ultimately, four potential biomarkers were screened out using LASSO regression and random forest algorithms: CEBPD, SOCS2, THBS1, and IFIT2. Using cMAP, 10 candidate therapeutic drugs, including lamotrigine, were identified. Expression of CEBPD and SOCS2 was consistently upregulated in NAFLD clinical datasets, FFA-treated HepG2 cells, and liver tissues of HFD-induced NAFLD mice, but not in AIS datasets or OGD-treated microglial cells. Furthermore, lamotrigine, cinnarizine, and lenvatinib significantly suppressed FFA-induced CEBPD and SOCS2 expression in HepG2 cells (p < 0.05), supporting their potential regulatory effects.
conclusionsThis study identified common DEGs between NAFLD and AIS and experimentally validated CEBPD as a potential marker, revealing possible common molecular mechanisms between the two diseases, providing new directions for future diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.